

Stephen J Russell

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2777610/stephen-j-russell-publications-by-citations.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|--------------------|--------------------------|----------------|-----------------|
| 321 papers | 14,731 citations | 64 h-index | 113 g-index |
| 327 ext. papers | 16,528 ext. citations | 6.1 avg, IF | 6.56 L-index |

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 321 | Improved survival in multiple myeloma and the impact of novel therapies. <i>Blood</i> , 2008 , 111, 2516-20 | 2.2 | 1753 |
| 320 | Oncolytic virotherapy. <i>Nature Biotechnology</i> , 2012 , 30, 658-70 | 44.5 | 947 |
| 319 | Engineering targeted viral vectors for gene therapy. <i>Nature Reviews Genetics</i> , 2007 , 8, 573-87 | 30.1 | 534 |
| 318 | History of oncolytic viruses: genesis to genetic engineering. <i>Molecular Therapy</i> , 2007 , 15, 651-9 | 11.7 | 441 |
| 317 | Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. <i>Blood</i> , 2004 , 103, 1641-6 | 2.2 | 272 |
| 316 | High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. <i>Cancer Research</i> , 2004 , 64, 4919-26 | 10.1 | 237 |
| 315 | Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. <i>Cancer Research</i> , 2010 , 70, 875-82 | 10.1 | 210 |
| 314 | Rescue and propagation of fully retargeted oncolytic measles viruses. <i>Nature Biotechnology</i> , 2005 , 23, 209-14 | 44.5 | 208 |
| 313 | Remission of disseminated cancer after systemic oncolytic virotherapy. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 926-33 | 6.4 | 202 |
| 312 | Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. <i>Blood</i> , 2001 , 97, 3746-54 | 2.2 | 200 |
| 311 | Retroviral vectors displaying functional antibody fragments. <i>Nucleic Acids Research</i> , 1993 , 21, 1081-5 | 20.1 | 192 |
| 310 | Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. <i>Clinical Cancer Research</i> , 2002 , 8, 2210-6 | 12.9 | 187 |
| 309 | Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. <i>Cancer Research</i> , 2003 , 63, 2462-9 | 10.1 | 187 |
| 308 | Engineering microRNA responsiveness to decrease virus pathogenicity. <i>Nature Medicine</i> , 2008 , 14, 1278-83 | 33.5 | 179 |
| 307 | Intraperitoneal therapy of ovarian cancer using an engineered measles virus. <i>Cancer Research</i> , 2002 , 62, 4656-62 | 10.1 | 168 |
| 306 | Systemic therapy of myeloma xenografts by an attenuated measles virus. <i>Blood</i> , 2001 , 98, 2002-7 | 2.2 | 153 |
| 305 | Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. <i>Clinical Cancer Research</i> , 2009 , 15, 7246-55 | 12.9 | 150 |

| | | | |
|-----|--|------|-----|
| 304 | Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. <i>Nature Medicine</i> , 2002 , 8, 527-31 | 50.5 | 148 |
| 303 | Viruses as anticancer drugs. <i>Trends in Pharmacological Sciences</i> , 2007 , 28, 326-33 | 13.2 | 144 |
| 302 | RNA viruses as virotherapy agents. <i>Cancer Gene Therapy</i> , 2002 , 9, 961-6 | 5.4 | 130 |
| 301 | Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. <i>Cancer Research</i> , 2015 , 75, 22-30 | 10.1 | 120 |
| 300 | Measles virus for cancer therapy. <i>Current Topics in Microbiology and Immunology</i> , 2009 , 330, 213-41 | 3.3 | 118 |
| 299 | Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018 , 8, 59 | 7 | 115 |
| 298 | Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. <i>Blood</i> , 2007 , 110, 2342-50 | 2.2 | 107 |
| 297 | Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. <i>Journal of Virology</i> , 2001 , 75, 2087-96 | 6.6 | 107 |
| 296 | The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. <i>Current Gene Therapy</i> , 2012 , 12, 33-47 | 4.3 | 105 |
| 295 | Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. <i>Molecular Therapy</i> , 2007 , 15, 114-22 | 11.7 | 105 |
| 294 | Modeling of cancer virotherapy with recombinant measles viruses. <i>Journal of Theoretical Biology</i> , 2008 , 252, 109-22 | 2.3 | 103 |
| 293 | Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines. <i>Cancer Cell</i> , 2018 , 33, 599-605 | 24.3 | 101 |
| 292 | Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. <i>Journal of Translational Medicine</i> , 2013 , 11, 20 | 8.5 | 97 |
| 291 | Recombinant measles viruses efficiently entering cells through targeted receptors. <i>Journal of Virology</i> , 2000 , 74, 9928-36 | 6.6 | 97 |
| 290 | Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. <i>Hepatology</i> , 2006 , 44, 1465-77 | 11.2 | 95 |
| 289 | A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. <i>Journal of Virology</i> , 1998 , 72, 9955-65 | 6.6 | 93 |
| 288 | Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. <i>Clinical Cancer Research</i> , 2006 , 12, 1868-75 | 12.9 | 92 |
| 287 | Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. <i>Experimental Hematology</i> , 2006 , 34, 713-20 | 3.1 | 90 |

| | | | |
|-----|---|------|----|
| 286 | Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 578-598 | 6.4 | 88 |
| 285 | Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. <i>Journal of Virology</i> , 2010 , 84, 1550-62 | 6.6 | 88 |
| 284 | Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. <i>Cancer Research</i> , 2006 , 66, 11840-50 ^{10.1} | 10.1 | 88 |
| 283 | Mathematical modeling of cancer radiovirotherapy. <i>Mathematical Biosciences</i> , 2006 , 199, 55-78 | 3.9 | 87 |
| 282 | A gene delivery system activatable by disease-associated matrix metalloproteinases. <i>Human Gene Therapy</i> , 1997 , 8, 729-38 | 4.8 | 86 |
| 281 | Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. <i>Human Gene Therapy</i> , 2001 , 12, 811-21 | 4.8 | 86 |
| 280 | Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. <i>Blood</i> , 2002 , 99, 2342-50 | 2.2 | 85 |
| 279 | Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 1163-76 | 5.4 | 84 |
| 278 | MicroRNAs and the regulation of vector tropism. <i>Molecular Therapy</i> , 2009 , 17, 409-16 | 11.7 | 84 |
| 277 | Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1054-81 | 6.4 | 81 |
| 276 | Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. <i>Blood</i> , 2016 , 127, 1449-58 | 2.2 | 81 |
| 275 | Genetically targeted radiotherapy for multiple myeloma. <i>Blood</i> , 2003 , 102, 489-96 | 2.2 | 80 |
| 274 | Designing and building oncolytic viruses. <i>Future Virology</i> , 2017 , 12, 193-213 | 2.4 | 79 |
| 273 | Erratum for Tesfay et al., PEGylation of Vesicular Stomatitis Virus Extends Virus Persistence in Blood Circulation of Passively Immunized Mice. <i>Journal of Virology</i> , 2015 , 89, 2453-2453 | 6.6 | 78 |
| 272 | Correction for Tesfay et al., Vesiculovirus Neutralization by Natural IgM and Complement. <i>Journal of Virology</i> , 2015 , 89, 1945-1946 | 6.6 | 78 |
| 271 | Modifying the host range properties of retroviral vectors. <i>Journal of Gene Medicine</i> , 1999 , 1, 300-11 | 3.5 | 78 |
| 270 | Oncolytic Virotherapy: A Contest between Apples and Oranges. <i>Molecular Therapy</i> , 2017 , 25, 1107-1116 ^{11.7} | 11.7 | 76 |
| 269 | Engineered measles virus as a novel oncolytic therapy against prostate cancer. <i>Prostate</i> , 2009 , 69, 82-91 ^{4.2} | 4.2 | 76 |

| | | | |
|-----|--|------|----|
| 268 | Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. <i>Molecular Therapy</i> , 2007 , 15, 677-86 | 11.7 | 76 |
| 267 | Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments. <i>Journal of Virology</i> , 2000 , 74, 295-304 | 6.6 | 74 |
| 266 | Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. <i>Current Cancer Drug Targets</i> , 2018 , 18, 177-187 | 2.8 | 73 |
| 265 | Engineering oncolytic measles virus to circumvent the intracellular innate immune response. <i>Molecular Therapy</i> , 2007 , 15, 588-97 | 11.7 | 73 |
| 264 | A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006 , 99, 177-84 | 4.4 | 72 |
| 263 | In vivo imaging and tumor therapy with the sodium iodide symporter. <i>Journal of Cellular Biochemistry</i> , 2003 , 90, 1079-86 | 4.7 | 72 |
| 262 | Retargeting gene delivery using surface-engineered retroviral vector particles. <i>Current Opinion in Biotechnology</i> , 2001 , 12, 461-6 | 11.4 | 72 |
| 261 | Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. <i>Molecular Therapy</i> , 2009 , 17, 2041-8 | 11.7 | 70 |
| 260 | Vesicular stomatitis virus expressing interferon- β s oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. <i>Oncotarget</i> , 2015 , 6, 33165-77 | 3.3 | 69 |
| 259 | Activation of membrane fusion by murine leukemia viruses is controlled in cis or in trans by interactions between the receptor-binding domain and a conserved disulfide loop of the carboxy terminus of the surface glycoprotein. <i>Journal of Virology</i> , 2001 , 75, 3685-95 | 6.6 | 68 |
| 258 | Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. <i>American Journal of Roentgenology</i> , 2009 , 192, 279-87 | 5.4 | 66 |
| 257 | Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. <i>Journal of Hepatology</i> , 2013 , 59, 999-1006 | 13.4 | 64 |
| 256 | In vivo selection of protease cleavage sites from retrovirus display libraries. <i>Nature Biotechnology</i> , 1998 , 16, 951-4 | 44.5 | 63 |
| 255 | Inverse Targeting of Retroviral Vectors: Selective Gene Transfer in a Mixed Population of Hematopoietic and Nonhematopoietic Cells. <i>Blood</i> , 1998 , 91, 1802-1809 | 2.2 | 63 |
| 254 | Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. <i>Molecular Therapy</i> , 2008 , 16, 1556-64 | 11.7 | 62 |
| 253 | Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. <i>American Journal of Roentgenology</i> , 2010 , 195, 341-9 | 5.4 | 59 |
| 252 | Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. <i>Molecular Therapy</i> , 2010 , 18, 1155-64 | 11.7 | 58 |
| 251 | Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. <i>Cancer Research</i> , 2009 , 69, 1459-68 | 10.1 | 58 |

| | | | |
|-----|--|------|----|
| 250 | Exploiting the high-affinity phosphonate-hydroxyapatite nanoparticle interaction for delivery of radiation and drugs. <i>Journal of Nanoparticle Research</i> , 2008 , 10, 141-150 | 2.3 | 58 |
| 249 | Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. <i>Cancer Research</i> , 2005 , 65, 5292-300 | 10.1 | 57 |
| 248 | Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. <i>Human Gene Therapy</i> , 2010 , 21, 451-62 | 4.8 | 56 |
| 247 | Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. <i>Human Gene Therapy</i> , 2010 , 21, 51-64 | 4.8 | 54 |
| 246 | Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 745-54 | 4.4 | 54 |
| 245 | Affinity thresholds for membrane fusion triggering by viral glycoproteins. <i>Journal of Virology</i> , 2007 , 81, 13149-57 | 6.6 | 54 |
| 244 | Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. <i>Human Gene Therapy</i> , 1999 , 10, 1533-44 | 4.8 | 54 |
| 243 | Viral vector targeting. <i>Current Opinion in Biotechnology</i> , 1999 , 10, 454-7 | 11.4 | 54 |
| 242 | Oncolytic Viruses: Priming Time for Cancer Immunotherapy. <i>BioDrugs</i> , 2019 , 33, 485-501 | 7.9 | 52 |
| 241 | Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. <i>Molecular Imaging and Biology</i> , 2006 , 8, 16-23 | 3.8 | 52 |
| 240 | Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016 , 91, 1123-1128 | 7.1 | 52 |
| 239 | Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019 , 54, 353-367 | 4.4 | 51 |
| 238 | PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. <i>Journal of Virology</i> , 2013 , 87, 3752-9 | 6.6 | 51 |
| 237 | A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. <i>Molecular Therapy</i> , 2005 , 12, 835-41 | 11.7 | 51 |
| 236 | MicroRNAs and oncolytic viruses. <i>Current Opinion in Virology</i> , 2015 , 13, 40-8 | 7.5 | 49 |
| 235 | Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018 , 32, 2240-2249 | 10.7 | 49 |
| 234 | Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. <i>Cancer Gene Therapy</i> , 2005 , 12, 593-9 | 5.4 | 49 |
| 233 | A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. <i>Human Gene Therapy</i> , 2000 , 11, 817-26 | 4.8 | 49 |

| | | | |
|-----|---|------|----|
| 232 | In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. <i>Molecular Imaging and Biology</i> , 2006 , 8, 324-32 | 3.8 | 48 |
| 231 | PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. <i>Experimental Hematology</i> , 2005 , 33, 784-95 | 3.1 | 48 |
| 230 | Oncolytic measles viruses for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2004 , 4, 1685-92 | 5.4 | 47 |
| 229 | Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017 , 92, 668-673 | 7.1 | 46 |
| 228 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017 , 130, 1198-1204 | 2.2 | 46 |
| 227 | Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. <i>American Journal of Hematology</i> , 2009 , 84, 401-7 | 7.1 | 46 |
| 226 | Concentration of viral vectors by co-precipitation with calcium phosphate. <i>Journal of Gene Medicine</i> , 2001 , 3, 188-94 | 3.5 | 46 |
| 225 | MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. <i>PLoS Pathogens</i> , 2010 , 6, e1000820 | 7.6 | 45 |
| 224 | The use of the NIS reporter gene for optimizing oncolytic virotherapy. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 15-32 | 5.4 | 44 |
| 223 | Multiple myeloma and the road to personalised medicine. <i>Lancet Oncology</i> , 2011 , 12, 617-9 | 21.7 | 44 |
| 222 | Use of attenuated paramyxoviruses for cancer therapy. <i>Expert Review of Vaccines</i> , 2010 , 9, 1275-302 | 5.2 | 44 |
| 221 | Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. <i>Prostate</i> , 2009 , 69, 1128-41 | 4.2 | 44 |
| 220 | Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 908-917 | 6.4 | 43 |
| 219 | Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1. <i>Science Translational Medicine</i> , 2016 , 8, 349ra99 | 17.5 | 41 |
| 218 | Reengineering paramyxovirus tropism. <i>Virology</i> , 2004 , 329, 217-25 | 3.6 | 41 |
| 217 | Modification of retroviral tropism by display of IGF-I. <i>Journal of Molecular Biology</i> , 1999 , 285, 485-94 | 6.5 | 41 |
| 216 | Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016 , 91, 585-9 | 7.1 | 40 |
| 215 | Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. <i>Journal of Virology</i> , 1998 , 72, 5313-7 | 6.6 | 39 |

| | | | |
|-----|---|------|----|
| 214 | Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy. <i>Scientific Reports</i> , 2013 , 3, 2375 | 4.9 | 38 |
| 213 | Infection and killing of multiple myeloma by adenoviruses. <i>Human Gene Therapy</i> , 2010 , 21, 179-90 | 4.8 | 38 |
| 212 | Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. <i>Virology</i> , 1997 , 234, 51-61 | 3.6 | 38 |
| 211 | Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 116 | 7 | 38 |
| 210 | Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. <i>Human Gene Therapy</i> , 2012 , 23, 484-91 | 4.8 | 37 |
| 209 | Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016 , 91, 984-8 | 7.1 | 37 |
| 208 | Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy. <i>Human Gene Therapy</i> , 2012 , 23, 295-301 | 4.8 | 36 |
| 207 | Oncolytic vaccines. <i>Expert Review of Vaccines</i> , 2013 , 12, 1155-72 | 5.2 | 35 |
| 206 | Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. <i>Human Gene Therapy Clinical Development</i> , 2013 , 24, 174-81 | 3.2 | 34 |
| 205 | Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 325, 157-66 | 3.4 | 34 |
| 204 | Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 316-326 | 6.1 | 34 |
| 203 | Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. <i>Blood</i> , 2006 , 107, 4063-70 ^{2.2} | | 33 |
| 202 | A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 472-483 | 6.4 | 33 |
| 201 | Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. <i>Molecular Therapy</i> , 2009 , 17, 1012-21 | 11.7 | 32 |
| 200 | Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein. <i>Journal of Gene Medicine</i> , 2004 , 6, 1082-91 | 3.5 | 32 |
| 199 | Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFN β IS. <i>Human Gene Therapy Clinical Development</i> , 2016 , 27, 111-22 | 3.2 | 30 |
| 198 | Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017 , 92, 50-55 | 7.1 | 30 |
| 197 | Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1354-1361 | 6.4 | 30 |

| | | | |
|-----|---|------|----|
| 196 | Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019 , 33, 527-531 | 10.7 | 30 |
| 195 | Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. <i>Leukemia</i> , 2020 , 34, 3310-3322 | 10.7 | 29 |
| 194 | Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 179-186 | 7.1 | 29 |
| 193 | Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , 2015 , 90, 981-5 | 7.1 | 28 |
| 192 | Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. <i>Cancer</i> , 2016 , 122, 2197-205 | 6.4 | 28 |
| 191 | MicroRNA-Targeted Mengovirus for Oncolytic Virotherapy. <i>Journal of Virology</i> , 2016 , 90, 4078-4092 | 6.6 | 26 |
| 190 | Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019 , 187, 588-594 | 4.5 | 26 |
| 189 | Vesiculovirus neutralization by natural IgM and complement. <i>Journal of Virology</i> , 2014 , 88, 6148-57 | 6.6 | 26 |
| 188 | Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands. <i>Journal of Virology</i> , 2013 , 87, 13543-55 | 6.6 | 26 |
| 187 | Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine. <i>BMC Cancer</i> , 2012 , 12, 508 | 4.8 | 26 |
| 186 | Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis. <i>Neoplasia</i> , 2010 , 12, 980-92 | 6.4 | 26 |
| 185 | Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017 , 313, H392-H407 | 5.2 | 25 |
| 184 | Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. <i>American Journal of Hematology</i> , 2015 , 90, 524-8 | 7.1 | 25 |
| 183 | Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses. <i>Molecular Therapy</i> , 2016 , 24, 306-317 | 11.7 | 23 |
| 182 | Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus. <i>Journal of Virology</i> , 2014 , 88, 8332-9 | 6.6 | 23 |
| 181 | Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters. <i>PLoS ONE</i> , 2013 , 8, e73759 | 3.7 | 23 |
| 180 | The utility of cells as vehicles for oncolytic virus therapies. <i>Current Opinion in Molecular Therapeutics</i> , 2008 , 10, 380-6 | | 23 |
| 179 | Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019 , 9, 32 | 7 | 22 |

| | | | |
|-----|---|------|----|
| 178 | Synthesis of ¹⁸ F-Tetrafluoroborate via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1454-9 | 8.9 | 22 |
| 177 | Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017 , 92, 1146-1155 | 7.1 | 22 |
| 176 | The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1284-9 | 4.3 | 21 |
| 175 | Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo. <i>Experimental Hematology</i> , 2013 , 41, 1038-49 | 3.1 | 21 |
| 174 | Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020 , 27, 13-16 | 2.7 | 21 |
| 173 | Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , 2016 , 91, 473-5 | 7.1 | 20 |
| 172 | Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy. <i>Molecular Therapy - Oncolytics</i> , 2014 , 1, 14005 | 6.4 | 20 |
| 171 | Enhancing cytokine-induced killer cell therapy of multiple myeloma. <i>Experimental Hematology</i> , 2013 , 41, 508-17 | 3.1 | 20 |
| 170 | Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies. <i>PLoS ONE</i> , 2013 , 8, e52306 | 3.7 | 20 |
| 169 | Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019 , 3, 1930-1938 | 7.8 | 20 |
| 168 | Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells. <i>Journal of General Virology</i> , 2009 , 90, 693-701 | 4.9 | 19 |
| 167 | Epitope selection from an uncensored peptide library displayed on avian leukosis virus. <i>Virology</i> , 2003 , 315, 313-21 | 3.6 | 19 |
| 166 | Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020 , 34, 1135-1143 | 10.7 | 19 |
| 165 | Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017 , 92, 549-554 | 7.1 | 18 |
| 164 | Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018 , 32, 1811-1815 | 10.7 | 18 |
| 163 | Antigenic Drift Defines a New D4 Subgenotype of Measles Virus. <i>Journal of Virology</i> , 2017 , 91, | 6.6 | 17 |
| 162 | Monoclonal gammopathy-associated thrombotic microangiopathy. <i>American Journal of Hematology</i> , 2019 , 94, E250-E253 | 7.1 | 17 |
| 161 | Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer. <i>Gynecologic Oncology</i> , 2014 , 132, 194-202 | 4.9 | 17 |

| | | | |
|-----|--|------|----|
| 160 | How to develop viruses into anticancer weapons. <i>PLoS Pathogens</i> , 2017 , 13, e1006190 | 7.6 | 17 |
| 159 | Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018 , 8, 125 | 7 | 17 |
| 158 | Synthesis and evaluation of F-hexafluorophosphate as a novel PET probe for imaging of sodium/iodide symporter in a murine C6-glioma tumor model. <i>Bioorganic and Medicinal Chemistry</i> , 2018 , 26, 225-231 | 3.4 | 16 |
| 157 | Converting tumor-specific markers into reporters of oncolytic virus infection. <i>Molecular Therapy</i> , 2009 , 17, 1395-403 | 11.7 | 16 |
| 156 | Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020 , 95, 310-315 | 7.1 | 16 |
| 155 | Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 811-814 | 10.7 | 15 |
| 154 | Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid. <i>Molecular Therapy</i> , 2011 , 19, 1041-7 | 11.7 | 15 |
| 153 | Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients. <i>Blood</i> , 2012 , 120, 201-201 | 2.2 | 15 |
| 152 | Oncolytic measles virus retargeting by ligand display. <i>Methods in Molecular Biology</i> , 2012 , 797, 141-62 | 1.4 | 15 |
| 151 | Safety, pharmacokinetics, metabolism and radiation dosimetry of F-tetrafluoroborate (F-TFB) in healthy human subjects. <i>EJNMMI Research</i> , 2017 , 7, 90 | 3.6 | 14 |
| 150 | Antibody neutralization of retargeted measles viruses. <i>Virology</i> , 2014 , 454-455, 237-46 | 3.6 | 14 |
| 149 | Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017 , 178, 888-895 | 4.5 | 14 |
| 148 | Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9. <i>Molecular Therapy - Oncolytics</i> , 2020 , 16, 63-74 | 6.4 | 14 |
| 147 | Cardiac AAV9 Gene Delivery Strategies in Adult Canines: Assessment by Long-term Serial SPECT Imaging of Sodium Iodide Symporter Expression. <i>Molecular Therapy</i> , 2015 , 23, 1211-1221 | 11.7 | 12 |
| 146 | Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020 , 10, 4 | 7 | 12 |
| 145 | Oncolytic vaccinia virotherapy for endometrial cancer. <i>Gynecologic Oncology</i> , 2014 , 132, 722-9 | 4.9 | 12 |
| 144 | Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread. <i>Molecular Therapy</i> , 2013 , 21, 1930-7 | 11.7 | 12 |
| 143 | Avian leukosis virus is a versatile eukaryotic platform for polypeptide display. <i>Virology</i> , 2003 , 315, 303-313 | 13.6 | 12 |

| | | | |
|-----|---|------|----|
| 142 | Recombinant mumps virus as a cancer therapeutic agent. <i>Molecular Therapy - Oncolytics</i> , 2016 , 3, 16019 | 6.4 | 12 |
| 141 | Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model. <i>Molecular Therapy</i> , 2016 , 24, 2109-2117 | 11.7 | 12 |
| 140 | Enhanced noninvasive imaging of oncology models using the NIS reporter gene and bioluminescence imaging. <i>Cancer Gene Therapy</i> , 2020 , 27, 179-188 | 5.4 | 12 |
| 139 | Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography. <i>Journal of Gene Medicine</i> , 2012 , 14, 590-7 | 3.5 | 11 |
| 138 | Primer on medical genomics. Part X: Gene therapy. <i>Mayo Clinic Proceedings</i> , 2003 , 78, 1370-83 | 6.4 | 11 |
| 137 | Combination Therapy with CC-5013 (Lenalidomide; Revlimid) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. <i>Blood</i> , 2004 , 104, 331-331 | 2.2 | 11 |
| 136 | Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017 , 92, 435-440 | 7.1 | 10 |
| 135 | Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome. <i>Journal of Gene Medicine</i> , 2009 , 11, 197-206 | 3.5 | 10 |
| 134 | Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors. <i>Cancer Gene Therapy</i> , 2000 , 7, 526-9 | 5.4 | 10 |
| 133 | Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020 , 95, 1280-1287 | 7.1 | 10 |
| 132 | Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018 , 93, 17-22 | 7.1 | 9 |
| 131 | Probing Morbillivirus Antisera Neutralization Using Functional Chimerism between Measles Virus and Canine Distemper Virus Envelope Glycoproteins. <i>Viruses</i> , 2019 , 11, | 6.2 | 9 |
| 130 | Gene therapy approaches for multiple myeloma. <i>Seminars in Hematology</i> , 2001 , 38, 268-75 | 4 | 9 |
| 129 | Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2057-2067 | 6.1 | 9 |
| 128 | Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016 , 101, 1102-9 | 6.6 | 9 |
| 127 | Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019 , 94, 306-311 | 7.1 | 9 |
| 126 | Stratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , 2019 , 185, 254-260 | 4.5 | 8 |
| 125 | Oncolytic Activity of Targeted Picornaviruses Formulated as Synthetic Infectious RNA. <i>Molecular Therapy - Oncolytics</i> , 2020 , 17, 484-495 | 6.4 | 8 |

| | | | |
|-----|--|------|---|
| 124 | Hemagglutinin-specific neutralization of subacute sclerosing panencephalitis viruses. <i>PLoS ONE</i> , 2018 , 13, e0192245 | 3.7 | 8 |
| 123 | Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1546-1577 | 6.4 | 8 |
| 122 | Inter-species variation in monovalent anion substrate selectivity and inhibitor sensitivity in the sodium iodide symporter (NIS). <i>PLoS ONE</i> , 2020 , 15, e0229085 | 3.7 | 7 |
| 121 | Intravascular cell delivery device for therapeutic VEGF-induced angiogenesis in chronic vascular occlusion. <i>Biomaterials</i> , 2014 , 35, 9012-22 | 15.6 | 7 |
| 120 | Natural history of amyloidosis isolated to fat and bone marrow aspirate. <i>British Journal of Haematology</i> , 2017 , 179, 170-172 | 4.5 | 7 |
| 119 | Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity. <i>Molecular Therapy - Oncolytics</i> , 2015 , 2, 15012 | 6.4 | 7 |
| 118 | Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019 , 33, 1273-1277 | 10.7 | 7 |
| 117 | Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019 , 94, 751-756 | 7.1 | 6 |
| 116 | Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 637-642 | 7.1 | 6 |
| 115 | Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV Cancers. <i>Molecular Therapy - Oncolytics</i> , 2018 , 10, 1-13 | 6.4 | 6 |
| 114 | Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. <i>Blood</i> , 2012 , 120, 3972-3972 | 2.2 | 6 |
| 113 | Mapping of Ion and Substrate Binding Sites in Human Sodium Iodide Symporter (hNIS). <i>Journal of Chemical Information and Modeling</i> , 2020 , 60, 1652-1665 | 6.1 | 5 |
| 112 | Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018 , 32, 1421-1426 | 10.7 | 5 |
| 111 | Enhancing the therapeutic index of radiation in multiple myeloma. <i>Drug Discovery Today Disease Mechanisms</i> , 2006 , 3, 515-522 | | 5 |
| 110 | Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma. <i>Oncotarget</i> , 2017 , 8, 63096-63109 | 3.3 | 5 |
| 109 | Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2021 , | 10.7 | 5 |
| 108 | Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 53-56 | 2 | 5 |
| 107 | Serotypic evolution of measles virus is constrained by multiple co-dominant B cell epitopes on its surface glycoproteins. <i>Cell Reports Medicine</i> , 2021 , 2, 100225 | 18 | 5 |

| | | | |
|-----|--|------|---|
| 106 | MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum. <i>PLoS Pathogens</i> , 2021 , 17, e1009283 | 7.6 | 5 |
| 105 | Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1834-1839 | 6.4 | 4 |
| 104 | Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 1268-1272 | 10.7 | 4 |
| 103 | Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018 , 53, 326-333 | 4.4 | 4 |
| 102 | Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019 , 26, 101-102 | 2.7 | 4 |
| 101 | Dual-Isotope SPECT Imaging with NIS Reporter Gene and Duramycin to Visualize Tumor Susceptibility to Oncolytic Virus Infection. <i>Molecular Therapy - Oncolytics</i> , 2019 , 15, 178-185 | 6.4 | 4 |
| 100 | MicroRNA-based Regulation of Picornavirus Tropism. <i>Journal of Visualized Experiments</i> , 2017 , | 1.6 | 4 |
| 99 | Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,. <i>Blood</i> , 2011 , 118, 3963-3963 | 2.2 | 4 |
| 98 | Pathogenic measles viruses cannot evolve to bypass vaccine-induced neutralizing antibodies | | 4 |
| 97 | Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 677-687 | 6.4 | 4 |
| 96 | A brief review of reporter gene imaging in oncolytic virotherapy and gene therapy. <i>Molecular Therapy - Oncolytics</i> , 2021 , 21, 98-109 | 6.4 | 4 |
| 95 | The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017 , 92, E507-E512 | 7.1 | 3 |
| 94 | Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1297-1304 | 4.4 | 3 |
| 93 | Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.. <i>Vaccine</i> , 2022 , | 4.1 | 3 |
| 92 | GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions. <i>Blood</i> , 2018 , 132, 961-961 | 2.2 | 3 |
| 91 | Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. <i>Blood</i> , 2005 , 106, 781-781 | 2.2 | 3 |
| 90 | Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. <i>Blood</i> , 2013 , 122, 3119-3119 | 2.2 | 3 |
| 89 | Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. <i>Blood</i> , 2015 , 126, 3177-3177 | 2.2 | 3 |

| | | | |
|----|---|------|---|
| 88 | Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 3317-3317 | 2.2 | 3 |
| 87 | Oncolytic Foamy Virus - generation and properties of a nonpathogenic replicating retroviral vector system that targets chronically proliferating cancer cells. <i>Journal of Virology</i> , 2021 , | 6.6 | 3 |
| 86 | Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021 , 106, 354-361 | 3.8 | 3 |
| 85 | Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021 , 96, 446-454 | 7.1 | 3 |
| 84 | For the Success of Oncolytic Viruses: Single Cycle Cures or Repeat Treatments? (One Cycle Should Be Enough). <i>Molecular Therapy</i> , 2018 , 26, 1876-1880 | 11.7 | 2 |
| 83 | Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 30-31 | 2.2 | 2 |
| 82 | Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. <i>Blood</i> , 2011 , 118, 2942-2942 | 2.2 | 2 |
| 81 | Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. <i>Blood</i> , 2013 , 122, 3117-3117 | 2.2 | 2 |
| 80 | Thrombotic Microangiopathy in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 5317-5317 | 2.2 | 2 |
| 79 | Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers. <i>Molecular Therapy - Oncolytics</i> , 2020 , 18, 546-555 | 6.4 | 2 |
| 78 | The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 451-460.e2 | 2 | 2 |
| 77 | New transgenic NIS reporter rats for longitudinal tracking of fibrogenesis by high-resolution imaging. <i>Scientific Reports</i> , 2018 , 8, 14209 | 4.9 | 2 |
| 76 | Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. <i>Cancer Immunology Research</i> , 2021 , 9, 1035-1046 | 12.5 | 2 |
| 75 | Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018 , 93, 1207-1210 | 7.1 | 1 |
| 74 | Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 183-188 | 2.7 | 1 |
| 73 | Genetic Targeting of Retroviral Vectors 2003 , 267-291 | | 1 |
| 72 | Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. <i>Blood</i> , 2020 , 136, 30-31 | 2.2 | 1 |
| 71 | Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019 , 134, 4334-4334 | 2.2 | 1 |

| | | | |
|----|--|-----|---|
| 70 | Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1905-1905 | 2.2 | 1 |
| 69 | Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020 , 136, 7-8 | 2.2 | 1 |
| 68 | In-111DAC Is a Novel Technique To Image Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3488-3488 | 2.2 | 1 |
| 67 | Tumor Associated Macrophages (TAM) in Skeletal Plasmacytomas of Patients with Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 114-114 | 2.2 | 1 |
| 66 | 14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. <i>Blood</i> , 2007 , 110, 2477-2477 ^{2.2} | 2.2 | 1 |
| 65 | The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2011 , 118, 2887-2887 | 2.2 | 1 |
| 64 | Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. <i>Blood</i> , 2012 , 120, 1858-1858 | 2.2 | 1 |
| 63 | Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , 2012 , 120, 946-946 | 2.2 | 1 |
| 62 | Survival Outcomes Of Very Young (. <i>Blood</i> , 2013 , 122, 2136-2136 | 2.2 | 1 |
| 61 | Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2013 , 122, 3095-3095 | 2.2 | 1 |
| 60 | Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 2082-2082 | 2.2 | 1 |
| 59 | Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , 2016 , 128, 3272-3272 | 2.2 | 1 |
| 58 | Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016 , 128, 3444-3444 | 2.2 | 1 |
| 57 | Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016 , 128, 4627-4627 | 2.2 | 1 |
| 56 | Engineering Oncolytic Measles Viruses for Targeted Cancer Therapy 2008 , 431-445 | | 1 |
| 55 | Serotypic Evolution of Measles Is Constrained by Multiple Codominant B-Cell Epitopes on Its Surface Glycoproteins. <i>SSRN Electronic Journal</i> , | 1 | 1 |
| 54 | Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019 , 134, 5490-5490 | 2.2 | 1 |
| 53 | Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis. <i>Blood</i> , 2016 , 128, 5480-5480 | 2.2 | 1 |

| | | | |
|----|--|------|---|
| 52 | Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020 , 95, E60-E62 | 7.1 | 1 |
| 51 | Collateral Lethal Effects of Complementary Oncolytic Viruses. <i>Molecular Therapy - Oncolytics</i> , 2020 , 18, 236-246 | 6.4 | 1 |
| 50 | A Novel Selectable Islet 1 Positive Progenitor Cell Reprogrammed to Expandable and Functional Smooth Muscle Cells. <i>Stem Cells</i> , 2016 , 34, 1354-68 | 5.8 | 1 |
| 49 | Improved Noninvasive InVivo Tracking of AAV-9 Gene Therapy Using the Perchlorate-Resistant Sodium Iodide Symporter from Minke Whale. <i>Molecular Therapy</i> , 2021 , 29, 236-243 | 11.7 | 1 |
| 48 | The long-lasting enigma of polycytidine (polyC) tract. <i>PLoS Pathogens</i> , 2021 , 17, e1009739 | 7.6 | 1 |
| 47 | Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma. <i>Cancer Treatment and Research Communications</i> , 2021 , 29, 100473 | 2 | 0 |
| 46 | MicroRNA-detargeting proves more effective than gene deletion for improving safety of oncolytic Mengovirus in a nude mouse model. <i>Molecular Therapy - Oncolytics</i> , 2021 , 23, 1-13 | 6.4 | 0 |
| 45 | Heterogeneous delivery is a barrier to the translational advancement of oncolytic virotherapy for treating solid tumors. <i>Virus Adaptation and Treatment</i> , 2014 , 11 | | |
| 44 | Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. <i>Transplantation</i> , 2021 , 105, 1615-1624 | 1.8 | |
| 43 | An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN γ IS). <i>Blood</i> , 2021 , 138, 1333-1333 | 2.2 | |
| 42 | Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021 , 138, 2700-2700 | 2.2 | |
| 41 | Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2021 , 138, 119-119 | 2.2 | |
| 40 | The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , 2021 , 138, 2650-2650 | 2.2 | |
| 39 | Fully Retargeted Oncolytic Measles Virus for Multiple Myeloma Therapy.. <i>Blood</i> , 2006 , 108, 5474-5474 | 2.2 | |
| 38 | Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1181-1181 | 2.2 | |
| 37 | Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis.. <i>Blood</i> , 2007 , 110, 3608-3608 | 2.2 | |
| 36 | Comparative Analysis of Staging Systems in AL Amyloidosis. <i>Blood</i> , 2018 , 132, 3228-3228 | 2.2 | |
| 35 | Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3159-3159 | | |

- 34 Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 3158-3158 2.2
- 33 Impact of Acquired Del(17p) in Patients with Multiple Myeloma. *Blood*, **2018**, 132, 4449-4449 2.2
- 32 Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. *Blood*, **2018**, 132, 3226-3226 2.2
- 31 Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. *Blood*, **2018**, 132, 4497-4497 2.2
- 30 Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). *Blood*, **2018**, 132, 4502-4502 2.2
- 29 Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. *Blood*, **2018**, 132, 5594-5594 2.2
- 28 Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. *Blood*, **2018**, 132, 3227-3227 2.2
- 27 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2018**, 132, 3268-3268 2.2
- 26 Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. *Blood*, **2018**, 132, 4615-4615 2.2
- 25 Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). *Blood*, **2019**, 134, 5523-5523 2.2
- 24 Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 5833-5833 2.2
- 23 Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. *Blood*, **2019**, 134, 1904-1904 2.2
- 22 The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 2197-2197 2.2
- 21 Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. *Blood*, **2015**, 126, 4176-4176 2.2
- 20 Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. *Blood*, **2015**, 126, 5303-5303 2.2
- 19 Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2016**, 128, 5615-5615 2.2
- 18 Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. *Blood*, **2016**, 128, 3273-3273 2.2
- 17 Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. *Blood*, **2016**, 128, 3251-3251 2.2

| | | |
|----|---|-----|
| 16 | Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. <i>Blood</i> , 2016 , 128, 3306-3306 | 2.2 |
| 15 | The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016 , 128, 1194-1194 | 2.2 |
| 14 | Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , 2016 , 128, 3269-3269 | 2.2 |
| 13 | Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 3338-3338 | 2.2 |
| 12 | Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. <i>Blood</i> , 2016 , 128, 3255-3255 | 2.2 |
| 11 | Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 2187-2187 | 2.2 |
| 10 | Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2012 , 120, 2973-2973 | 2.2 |
| 9 | Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. <i>Blood</i> , 2012 , 120, 448-448 | 2.2 |
| 8 | Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 1988-1988 | 2.2 |
| 7 | Biological Therapy for Multiple Myeloma 2014 , 141-158 | |
| 6 | Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1979-1979 | 2.2 |
| 5 | Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3209-3209 | 2.2 |
| 4 | Inter-species variation in monovalent anion substrate selectivity and inhibitor sensitivity in the sodium iodide symporter (NIS) 2020 , 15, e0229085 | |
| 3 | Inter-species variation in monovalent anion substrate selectivity and inhibitor sensitivity in the sodium iodide symporter (NIS) 2020 , 15, e0229085 | |
| 2 | Inter-species variation in monovalent anion substrate selectivity and inhibitor sensitivity in the sodium iodide symporter (NIS) 2020 , 15, e0229085 | |
| 1 | Inter-species variation in monovalent anion substrate selectivity and inhibitor sensitivity in the sodium iodide symporter (NIS) 2020 , 15, e0229085 | |